Please sign in to follow a disease.
Dermis disorder
MONDO:0021154A disease that involves the dermis.
Also known as: dermis disease, dermis disease or disorder, disease of dermis, disease or disorder of dermis, disorder of dermis, other dermis disorder
103 clinical trials for this condition and its sub-types, 0 tagged with Dermis disorder itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Part of
Sub-types of Dermis disorder
-
Dermis tumor 0 trials · 90 incl. sub-types
8 sub-types
- Malignant dermis tumor 0 trials · 87 incl. sub-types Sub-types →
- Leiomyoma cutis 2 trials Sub-types →
- Cutaneous fibrous histiocytoma 1 trial
- Cutaneous granular cell tumor 0 trials · 1 incl. sub-types Sub-types →
- Cutaneous mastocytosis 1 trial Sub-types →
- Skin glomus tumor 1 trial Sub-types →
- Angioma serpiginosum 0 trials Sub-types →
- Juvenile hyaline fibromatosis 0 trials
-
Primary cutaneous amyloidosis 4 trials · 5 incl. sub-types
5 sub-types
- Lichen amyloidosis 2 trials
- Familial primary localized cutaneous amyloidosis 1 trial Sub-types →
- Macular amyloidosis 1 trial
- Amyloidosis cutis dyschromia 0 trials
- Nodular cutaneous amyloidosis 0 trials
-
Primary anetoderma 4 trials
-
Mixed dermis disorder 0 trials · 3 incl. sub-types
6 sub-types
- Aplasia cutis congenita 3 trials Sub-types →
- Aplasia cutis congenita-intestinal lymphangiectasia syndrome 0 trials
- Linear skin defects with multiple congenital anomalies 0 trials Sub-types →
- Recessive aplasia cutis congenita of limbs 0 trials
- Scalp defects-postaxial polydactyly syndrome 0 trials
- Scalp-ear-nipple syndrome 0 trials
-
Elastoma 1 trial
-
Annular erythema of infancy 0 trials
-
Antecubital pterygium syndrome 0 trials
-
Atrophoderma of Pierini and Pasini 0 trials
-
Confetti-like macular atrophy 0 trials
-
Dermochondrocorneal dystrophy 0 trials
-
Elastoderma 0 trials
-
Elastosis perforans serpiginosa 0 trials
-
Familial anetoderma 0 trials
-
Familial cutaneous collagenoma 0 trials
-
Late-onset focal dermal elastosis 0 trials
-
Lichen myxedematosus 0 trials
3 sub-types
- Atypical lichen myxedematosus 0 trials Sub-types →
- Localized lichen myxedematosus 0 trials Sub-types →
- Scleromyxedema 0 trials
-
Linear atrophoderma of Moulin 0 trials
-
Linear focal dermal elastosis 0 trials
-
Lipoid proteinosis 0 trials
-
Mid-dermal elastolysis 0 trials
-
Necrobiosis lipoidica 0 trials
-
Papular elastorrhexis 0 trials
-
Primary cutis verticis gyrata 0 trials
3 sub-types
-
Progressive osseous heteroplasia 0 trials
-
White fibrous papulosis of the neck 0 trials
Most studied deeper sub-types
-
Experimental combo therapy shows promise in advanced cancers, but trial halted early
Disease control Stopped earlyThis study tested whether injecting vidutolimod directly into tumors plus giving cemiplimab through a vein could shrink cancers that have spread. The trial included 77 people with several types of advanced cancer. Unfortunately, the study was stopped early, so we have less inform…
Phase 2 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
Experimental cancer drug trial halted early
Disease control Stopped earlyThis early-stage study tested a new drug called PF-07265807 in people with advanced or metastatic solid tumors that had spread. The main goals were to find a safe dose and check for side effects. The trial was terminated early, so results are limited.
Phase 1 • Sponsor: Pfizer • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
Experimental triple therapy for advanced cancers shows early promise but trial halted
Disease control Stopped earlyThis early-phase trial tested the drug plinabulin combined with radiation and immunotherapy in 19 people with advanced cancers (like lung, bladder, or melanoma) that had stopped responding to standard immunotherapy. The goal was to see if the combination was safe and could shrink…
Phase 1/2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:26 UTC
-
Experimental cancer combo shows early promise but study halted
Disease control Stopped earlyThis early-phase trial tested a new drug called nanrilkefusp alfa, which helps activate immune cells, both alone and combined with the immunotherapy pembrolizumab. It included 115 people with various advanced solid tumors that had stopped responding to standard treatments. The st…
Phase 1 • Sponsor: SOTIO Biotech AG • Aim: Disease control
Last updated Jun 27, 2026 12:01 UTC
-
Promising cancer combo trial halted after just 2 patients
Disease control Stopped earlyThis early-phase study tested a radioactive drug called 225Ac-SSO110 combined with standard immune checkpoint inhibitors for people with advanced small cell lung cancer or Merkel cell carcinoma. The goal was to check safety and find the right dose. However, the trial was terminat…
Phase 1/2 • Sponsor: Ariceum Therapeutics GmbH • Aim: Disease control
Last updated Jun 27, 2026 09:02 UTC
-
Gene therapy shot for dry AMD shows promise in early trial
Disease control Stopped earlyThis study tested a single injection of a gene therapy called GT005 in 98 people with geographic atrophy, an advanced form of dry age-related macular degeneration that causes vision loss. The goal was to see if the treatment could slow the growth of damaged areas in the eye and c…
Phase 2 • Sponsor: Gyroscope Therapeutics Limited • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
Gene therapy shot for dry AMD shows promise but trial halted early
Disease control Stopped earlyThis study tested a single injection of GT005, a gene therapy, in 255 people with geographic atrophy from dry age-related macular degeneration. The goal was to see if it could slow the growth of blind spots in the eye. The trial was terminated early, so we have less data than hop…
Phase 2 • Sponsor: Gyroscope Therapeutics Limited • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
Experimental gene injection targets dry AMD
Disease control Stopped earlyThis early-stage trial tested a gene therapy called GT005 for dry age-related macular degeneration (AMD), a leading cause of vision loss. The therapy delivers a working gene to the retina via a single injection. The study enrolled 56 people and focused on safety and dosing, but w…
Phase 1/2 • Sponsor: Gyroscope Therapeutics Limited • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
New cancer drug OC-001 tested in advanced tumors – trial ends early
Disease control Stopped earlyThis early-phase trial tested an experimental drug called OC-001, given alone or with the immunotherapy avelumab, in 73 people with various advanced or metastatic cancers (like lung, breast, and bladder cancer). The main goals were to check safety and how the drug moves through t…
Phase 1/2 • Sponsor: Ocellaris Pharma, Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:11 UTC
-
Cancer-Fighting virus injected directly into tumors shows promise in early trial
Disease control Stopped earlyThis early-phase trial tested a new treatment called BT-001, a virus designed to infect and kill cancer cells, given alone or with the immunotherapy drug pembrolizumab. The study involved 31 people with advanced solid tumors like melanoma, lung cancer, or sarcoma that had spread.…
Phase 1/2 • Sponsor: Transgene • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC
-
Experimental combo for skin cancer shows early promise but study halted
Disease control Stopped earlyThis study tested whether adding an immune-boosting drug (NT-I7) to a standard immunotherapy (atezolizumab) could help people with advanced skin cancers like melanoma, Merkel cell carcinoma, and squamous cell carcinoma. The trial included 31 adults whose cancer had not responded …
Phase 1/2 • Sponsor: NeoImmuneTech • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
Experimental cancer drug trial ends early
Disease control Stopped earlyThis early-stage study tested an experimental drug called INCB099318 in people with advanced solid tumors that had stopped responding to standard treatments. The main goal was to check the drug's safety and how the body processes it. The study was terminated early, so results are…
Phase 1 • Sponsor: Incyte Corporation • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC